GlassScriptPhysician profile
Paula M Moch
NPI 1851633804
$5,249.80
in general payments reported to CMS, 2019-2025
45 companies · $1,505 in 2025
The $1,505 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $282 · 2022: $356 · 2023: $1,481 · 2024: $1,625 · 2025: $1,505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,611.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $642.89 | 2022-2025 | Airsupra, Tezspire, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $504.65 | 2021-2025 | Entyvio, Eohilia, Glassia |
| Abbvie INC. | $372.03 | 2023-2025 | |
| Harmony Biosciences LLC | $301.47 | 2023-2025 | Wakix |
| Regeneron Healthcare Solutions, INC. | $280.64 | 2021-2025 | Dupixent |
| Grifols USA, LLC | $259.81 | 2021-2024 | Prolastin-C Liquid, Xembify |
| Melinta Therapeutics, LLC | $253.79 | 2022-2025 | Orbactiv, Kimyrsa, Rezzayo |
| Glaxosmithkline, LLC. | $237.11 | 2023-2025 | Nucala, Shingrix |
| Merck Sharp & Dohme LLC | $221.62 | 2022-2025 | Dificid, Zerbaxa, Delstrigo |
| Janssen Biotech, INC. | $215.96 | 2021-2025 | Stelara, Tremfya, Simponi |
| Baxter Healthcare | $214.29 | 2023-2025 | Hillrom - Vest System Model 105 Home Care |
| United Therapeutics Corporation | $170.61 | 2023-2025 | Tyvaso, Tyvaso |
| Pfizer INC. | $136.86 | 2023-2025 | |
| Qol Medical, LLC | $124.08 | 2023-2025 | Sucraid, Sucraid |
| Aimmune Therapeutics, INC. | $105.92 | 2024-2025 | Zenpep, Vowst |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $99.20 | 2023 | Rebyota |
| Intercept Pharmaceuticals, INC. | $96.29 | 2023-2024 | Ocaliva |
| Astellas Pharma US INC | $94.95 | 2021 | |
| Lilly USA, LLC | $82.84 | 2021-2025 | Mounjaro, Zepbound, Omvoh |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.75 | 2022-2025 | Ofev |
| Jazz Pharmaceuticals INC. | $68.22 | 2023-2025 | |
| Daiichi Sankyo INC. | $67.50 | 2022-2023 | Injectafer |
| La Jolla Pharmaceutical Company | $50.99 | 2022-2023 | Giapreza |
| Ardelyx, INC. | $47.59 | 2023-2025 | Ibsrela |
| Mylan Specialty L.P. | $46.39 | 2022-2024 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.22 | 2023 | Xifaxan, Plenvu |
| Mallinckrodt Hospital Products INC. | $42.82 | 2024-2025 | Acthar |
| Kerecis Limited | $41.44 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Ani Pharmaceuticals, INC. | $37.21 | 2025 | Purified Cortrophin Gel |
| Phadia US INC. | $32.05 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $31.30 | 2021 | |
| Pharmacosmos Therapeutics INC. | $27.78 | 2023 | Monoferric |
| Phathom Pharmaceuticals, INC. | $24.63 | 2025 | Voquezna |
| Viatris Specialty LLC | $20.51 | 2025 | Yupelri |
| Sun Pharmaceutical Industries INC. | $19.08 | 2021 | |
| Amgen INC. | $18.68 | 2025 | Tavneos |
| Integra Lifesciences Corporation | $17.96 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Nestle Healthcare Nutrition INC. | $16.46 | 2023 | |
| Alexion Pharmaceuticals, INC. | $15.89 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.04 | 2023 | Xarelto |
| Ipsen Biopharmaceuticals, INC | $14.32 | 2025 | Iqirvo |
| Pharming Healthcare, INC. | $14.06 | 2023 | Ruconest |
| Celgene Corporation | $13.74 | 2021 | |
| Ucb, INC. | $13.74 | 2022 | |
| Insmed, INC. | $13.42 | 2024 | Arikayce |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Moch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.